Specialty Pharma Journal Specialty, Precision & Technology
BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its ongoing Phase 3 development program of its investigational compound VX-661 in combination with ivacaftor, which includes four studies that together are expected to enroll more than 1,000 people with cystic fibrosis (CF). Based on a planned interim futility …
Tag Archives: VX-661
August, 2016
March, 2015
-
23 March
Vertex’s Experimental Cystic Fibrosis Drug Meets Phase 2 Study Goals
Vertex Pharmaceuticals announced results from a mid-stage study evaluating its experimental cystic fibrosis drug in combination with Kalydeco (ivacaftor). While the company said that its VX-661 in combination with ivacaftor was generally well tolerated and patients receiving the combination saw an increase in the amount of air they could exhale …